stem-cell-congress-cardiology-2018-posters

Biomedical Research

Volume 29

Page 59

allied

academies

CARDIOLOGY AND CARDIOVASCULAR MEDICINE

STEM CELLS AND REGENERATIVE MEDICINE

International Conference on

J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

FIBRIN SCAFFOLD COULD PROMOTE SURVIVAL OF THE HUMAN

ADIPOSE–DERIVED STEM CELLS DURING DIFFERENTIATION INTO

CARDIOMYOCYTE-LIKE CELLS

Parvin Salehinejad

Kerman University of Medical Sciences, Iran

uman adipose-derived stem cells (hADSCs) are capable of differentiating into many cells including cardiac cells.

Different types of scaffolds are used for cell differentiation, but the best is yet to be determined. In this study, fibrin

scaffold (3D) was fabricated using human plasma fibrinogen compared with culture plates (2D) for the growth and

differentiation of hADSCs into cardiomyocyte-like cells. For this purpose, after approving the properties of the isolated

hADSCs and fibrin scaffold, four biochemical tests were employed to determine the relative growth rate of hADSCs in 2D

and 3D cultures. To examine the effects of two different culture systems on cardiomyogenic differentiation, hADSCs were

treated with 10 or 50 µM 5-azacytidine (5-Aza) for 24 h and followed until 10 weeks. The results indicated that the growth

of hADSCs in 3D significantly increased after the 7

day (P < 0.05). Western blot, qRT-PCR and immunochemistry assays

were used to evaluate the rate of cardiac differentiation, which showed significantly higher expression of special cardiac

genes such as

NKX2.5, Cx43, MLC2v, βMHC, HAND1, HAND2

and

cTnI

(P < 0.05) in the treated hADSCs with 50 µM 5-Aza in

the 3D group. However, the expression level of the specific cardiac proteins in 3D was not significant using western blot and

immunofluorescence staining. In conclusion, this study suggests that the fibrin scaffold with compressive stress of 107.74

kpa can keep the cells alive for 10 weeks and also allows a higher and sooner differentiation of hADSCs into cardiomyocyte-

like cells treated with 50 µM 5-Aza.

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006